A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Clinical trial NCT05907304 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05907304
Sponsor: Erasca, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced or Metastatic Solid Tumors

Start date: 2023-08-17
Primary completion: 2025-07-01
Enrollment: 86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.